Global Rifampicin Market Size, by Route of Administration (Oral, Intravenous Injection), by Application (Tuberculosis, Leprosy) & Region - Key Manufacturers, Analysis, Growth Trends, and Forecast till 2026

  • Category : Healthcare and Pharma
  • |
  • ID : 1177480
  • |
  • Date : August 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Rifampicin Market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. Increasing prevalence of tuberculosis cases is driving the market growth. However, availability of better alternatives might restrict the growth of the market.

The global rifampicin market is primarily segmented based on route of administration, application and regions.

On the basis of route of administration, the market is split into:
* Oral
* Intravenous Injection

On the basis of application, the market is split into:
* Tuberculosis
* Leprosy
* Legionnaire\'s Disease
* Other Applications

Moreover, the market is classified based on region and countries as follows:
* North America- U.S., Canada
* Europe- U.K., France, Germany, Italy and Rest of Europe
* Asia-Pacific- China, Japan, India and Rest of Asia Pacific
* South America- Brazil, Mexico and Rest of South America
* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players:
The key players profiled in the market include:
* Sanofi
* Wellona Pharma
* AVANSCURE LIFESCIENCES PVT. LTD
* Hebei Xingang Pharmaceutical Co., Ltd.
* Mercator Pharmaceutical Solutions
* ASIAN PHARMACY
* A. S. JOSHI & COMPANY
* Pfizer Inc.
* Sunij Pharma
* Novartis International AG

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:
* Global, regional, country, route of administration, application, end user and market size and their forecast from 2015-2026
* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market
* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies
* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points
* Analysis on key players’ strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market
* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors’ short term and long term strategies
* Detailed insights on emerging regions route of administration, application, end user and options with qualitative and quantitative information and facts

Target Audience:
* Rifampicin Manufacturers
* Traders, Importers, and Exporters
* Raw Material Suppliers and Distributors
* Research and Consulting Firms
* Government and Research Organizations
* Associations and Industry Bodies

Research Methodology:
The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:
* Manufacturers
* Suppliers
* Distributors
* Government Body & Associations
* Research Institutes

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Global Rifampicin Market Overview
4.1. Market Segmentation & Scope
4.2. Market Trends
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Supply Chain Analysis
4.3. Global Rifampicin Market - Porter\'s Five Forces Analysis
4.4. Global Rifampicin Market - PESTEL Analysis

5. Global Rifampicin Market, by Route of Administration
5.1. Global Rifampicin Market, Size and Forecast, 2015-2026
5.2. Global Rifampicin Market by Oral, 2015-2026
5.2.1. Key driving factors, trends and opportunities
5.2.2. Market size and forecast, 2015-2026
5.3. Global Rifampicin Market by Intravenous Injection, 2015-2026
5.3.1. Key driving factors, trends and opportunities
5.3.2. Market size and forecast, 2015-2026

6. Global Rifampicin Market, by Application
6.1. Global Rifampicin Market, Size and Forecast, 2015-2026
6.2. Global Rifampicin Market by Tuberculosis, 2015-2026
6.2.1. Key driving factors, trends and opportunities
6.2.2. Market size and forecast, 2015-2026
6.3. Global Rifampicin Market by Leprosy, 2015-2026
6.3.1. Key driving factors, trends and opportunities
6.3.2. Market size and forecast, 2015-2026
6.4. Global Rifampicin Market by Legionnaire\'s Disease, 2015-2026
6.4.1. Key driving factors, trends and opportunities
6.4.2. Market size and forecast, 2015-2026
6.5. Global Rifampicin Market by Other Applications, 2015-2026
6.5.1. Key driving factors, trends and opportunities
6.5.2. Market size and forecast, 2015-2026

7. Global Rifampicin Market by Region
7.1. Rifampicin Market Regional Analysis, 2015-2026
7.2. Global Rifampicin Market Revenue (USD Million) by Region, 2015-2026
7.3. North America Rifampicin Market, 2015-2026
7.3.1. North America Rifampicin Market Size and Forecast, 2015-2026
7.3.2. North America Rifampicin Market by Country, 2015-2026
7.3.2.1. U.S. Rifampicin Market, 2015-2026
7.3.2.2. Canada Rifampicin Market, 2015-2026
7.4. Europe Rifampicin Market, 2015-2026
7.4.1. Europe Rifampicin Market Size and Forecast, 2015-2026
7.4.2. Europe Rifampicin Market by Country, 2015-2026
7.4.2.1. Germany Rifampicin Market, 2015-2026
7.4.2.2. France Rifampicin Market, 2015-2026
7.4.2.3. Italy Rifampicin Market, 2015-2026
7.4.2.4. UK Rifampicin Market, 2015-2026
7.4.2.5. Spain Rifampicin Market, 2015-2026
7.4.2.6. Rest of Europe Rifampicin Market, 2015-2026
7.5. Asia Pacific Rifampicin Market, 2015-2026
7.5.1. Asia Pacific Rifampicin Market Size and Forecast, 2015-2026
7.5.2. Asia Pacific Rifampicin Market by Country, 2015-2026
7.5.2.1. Japan Rifampicin Market, 2015-2026
7.5.2.2. China Rifampicin Market, 2015-2026
7.5.2.3. India Rifampicin Market, 2015-2026
7.5.2.4. Rest of Asia Pacific Rifampicin Market, 2015-2026
7.6. South America Rifampicin Market, 2015-2026
7.6.1. South America Rifampicin Market Size and Forecast, 2015-2026
7.6.2. South America Rifampicin Market by Country, 2015-2026
7.6.2.1. Mexico Rifampicin Market, 2015-2026
7.6.2.2. Brazil Rifampicin Market, 2015-2026
7.6.2.3. Rest of South America Rifampicin Market, 2015-2026
7.7. Middle East & Africa Rifampicin Market, 2015-2026
7.7.1. Middle East & Africa Rifampicin Market Size and Forecast, 2015-2026
7.7.2. Middle East & Africa Rifampicin Market by Country, 2015-2026
7.7.2.1. Saudi Arabia Rifampicin Market, 2015-2026
7.7.2.2. South Africa Rifampicin Market, 2015-2026
7.7.2.3. Rest of Middle East & Africa Rifampicin Market, 2015-2026

8. Competitive Landscape
8.1. Introduction
8.2. Market Share Analysis/Top Player Positioning, 2018

9. Company Profiles
9.1. Sanofi
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Product Benchmarking
9.1.4. Key Developments
9.2. Wellona Pharma
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Product Benchmarking
9.2.4. Key Developments
9.3. AVANSCURE LIFESCIENCES PVT. LTD
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Product Benchmarking
9.3.4. Key Developments
9.4. Hebei Xingang Pharmaceutical Co., Ltd.
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Product Benchmarking
9.4.4. Key Developments
9.5. Mercator Pharmaceutical Solutions
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Product Benchmarking
9.5.4. Key Developments
9.6. ASIAN PHARMACY
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Product Benchmarking
9.6.4. Key Developments
9.7. A. S. JOSHI and COMPANY
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Product Benchmarking
9.7.4. Key Developments
9.8. Pfizer Inc.
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Product Benchmarking
9.8.4. Key Developments
9.9. Sunij Pharma
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Product Benchmarking
9.9.4. Key Developments
9.10. Novartis International AG
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Product Benchmarking
9.10.4. Key Developments

10. Key Insights

Content are not available

Choose License Type